Oncocyte Corp financial data

Symbol
OCX on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
15 Cushing, Irvine, CA
State of incorporation
CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 99.4 % -53.2%
Debt-to-equity 335 % +186%
Return On Equity -268 % -79.2%
Return On Assets -59.4 % +8%
Operating Margin -6.15K % -337%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16.8M shares +104%
Common Stock, Shares, Outstanding 13.4M shares +61.9%
Entity Public Float 18.8M USD -72.6%
Common Stock, Value, Issued 327M USD +5.38%
Weighted Average Number of Shares Outstanding, Basic 13.7M shares +66.1%
Weighted Average Number of Shares Outstanding, Diluted 13.7M shares +66.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 709K USD -51.5%
Cost of Revenue 736K USD -15.5%
Research and Development Expense 9.99M USD +22.9%
Selling and Marketing Expense 3.32M USD +30.5%
General and Administrative Expense 9.4M USD -35.3%
Operating Income (Loss) -43.6M USD -112%
Nonoperating Income (Expense) 449K USD -8.33%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -43.1M USD -107%
Net Income (Loss) Attributable to Parent -43.1M USD +24%
Earnings Per Share, Basic -4.74 USD/shares +58.9%
Earnings Per Share, Diluted -4.74 USD/shares +58.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.36M USD -75.6%
Accounts Receivable, after Allowance for Credit Loss, Current 209K USD -64.8%
Inventory, Net 232K USD
Assets, Current 4.79M USD -71.7%
Property, Plant and Equipment, Net 6.19M USD +20.8%
Operating Lease, Right-of-Use Asset 4.04M USD +15.3%
Intangible Assets, Net (Excluding Goodwill) 56.5M USD -0.16%
Goodwill 18.7M USD +1.37%
Other Assets, Noncurrent 699K USD +34.4%
Assets 70.2M USD -13.9%
Accounts Payable, Current 872K USD -23.2%
Accrued Liabilities, Current 1.91M USD +10.7%
Liabilities, Current 9.09M USD +13.2%
Liabilities 60.5M USD +54.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 57K USD +78.1%
Retained Earnings (Accumulated Deficit) -317M USD -21%
Stockholders' Equity Attributable to Parent 9.71M USD -73.1%
Liabilities and Equity 70.2M USD -13.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.83M USD +53.9%
Net Cash Provided by (Used in) Financing Activities -28K USD +92.1%
Net Cash Provided by (Used in) Investing Activities -24K USD +98.3%
Common Stock, Shares Authorized 230M shares 0%
Common Stock, Shares, Issued 13.4M shares +61.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.85M USD +60.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.1M USD -59%
Interest Paid, Excluding Capitalized Interest, Operating Activities 13K USD -70.5%
Deferred Tax Assets, Valuation Allowance 67.3M USD +23.7%
Deferred Tax Assets, Gross 82.6M USD +15.1%
Operating Lease, Liability 2.84M USD
Depreciation 450K USD +56.8%
Payments to Acquire Property, Plant, and Equipment 24K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -43.1M USD +24%
Lessee, Operating Lease, Liability, to be Paid 3.3M USD -8.87%
Property, Plant and Equipment, Gross 8.84M USD +57.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.18M USD +36%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.14M USD +26.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 465K USD -35.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 695K USD -22.7%
Deferred Tax Assets, Operating Loss Carryforwards 61.8M USD +7.08%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 2.3M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 695K USD -22.7%
Operating Lease, Payments 272K USD -4.9%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 88K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 15.3M USD -11.8%
Share-based Payment Arrangement, Expense 1.74M USD -64.5%